<PAGE>
As filed with the Securities and Exchange Commission on January 5, 2001
Registration No. 333-________
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): JANUARY 5, 2001
CV THERAPEUTICS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 0-21643 45-1570294
(STATE OR OTHER JURISDICTION OF (COMMISSION FILE NO.) (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.)
------------------
3172 PORTER DRIVE
PALO ALTO, CALIFORNIA 94304
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES INCLUDING ZIP CODE)
(650) 812-0585
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
<PAGE>
ITEM 5. OTHER EVENTS
On January 5, 2001, the Registrant publicly disseminated a press release
announcing that the Registrant completed enrollment of its originally planned
462 patients in the Phase III CARISA (Combination Assessment of Ranolazine In
Stable Angina) trial, but plans to enroll an additional 186 patients based on a
blinded interim assessment.
The foregoing description is qualified in its entirety by reference to the
Registrant's Press Release dated January 5, 2001, a copy of which is attached
hereto as Exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(c) Exhibits.
99.1 Registrant's Press Release dated January 5, 2001.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CV THERAPEUTICS, INC.
By: /s/ DANIEL K. SPIEGELMAN
-------------------------
Daniel K. Spiegelman
SENIOR VICE PRESIDENT AND
CHIEF FINANCIAL OFFICER
(Principal financial and accounting officer)
